Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Onkologia w Praktyce Klinicznej - Edukacja
MENU
Na skróty Ahead of print Zdeponuj artykuł Nagroda imienia Profesora Krzysztofa Krzemienieckiego Zalecenia postępowania diagnostyczno-terapeutycznego

dostęp otwarty

Tom 8, Nr 6 (2022)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2021-12-30
Pokaż PDF Pokaż HTML
Pobierz cytowanie

Postępowanie diagnostyczno-terapeutyczne u chorych na czerniaki — zalecenia ekspertów

Piotr Rutkowski1, Piotr J. Wysocki23, Katarzyna Kozak1, Anna Nasierowska-Guttmejer45, Arkadiusz Jeziorski6, Wojciech M. Wysocki7, Ewa Kalinka8, Tomasz Świtaj1, Grażyna Kamińska-Winciorek9, Anna M. Czarnecka1, Hanna Koseła-Paterczyk1, Bożena Cybulska-Stopa10, Piotr Wiśniewski11, Anna Szumera-Ciećkiewicz1112, Marcin Zdzienicki1, Marek Ziobro10, Jacek Fijuth13, Andrzej Kawecki14, Andrzej Tysarowski11, Bożena Romanowska-Dixon15, Anna Markiewicz15, Marek Dedecjus16, Tomasz Kubiatowski17, Kamil Dolecki18, Hanna Tchórzewska-Korba19, Lidia Rudnicka20, Witold Owczarek21, Maciej Krzakowski22
Onkol Prakt Klin Edu 2022;8(6):387-423.
Afiliacje
  1. Klinika Nowotworów Tkanek Miękkich, Kości i Czerniaków, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie — Państwowy Instytut Badawczy w Warszawie
  2. Oddział Kliniczny Onkologii, Szpital Uniwersytecki w Krakowie
  3. Klinika i Katedra Onkologii, Uniwersytet Jagielloński — Collegium Medicum w Krakowie
  4. Zakład Patomorfologii CSK MSWiA w Warszawie
  5. Uczelnia Łazarskiego w Warszawie
  6. Klinika Chirurgii Onkologicznej, Uniwersytet Medyczny w Łodzi, II Oddział Chirurgii Onkologicznej Wojewódzkiego Wielodyscyplinarnego Centrum Onkologii i Traumatologii im. Mikołaja Kopernika w Łodzi
  7. Katedra Chirurgii Wydziału Lekarskiego i Nauk o Zdrowiu Krakowskiej Akademii im. A. Frycza-Modrzewskiego w Krakowie
  8. Klinika Onkologii, Instytut–Centrum Zdrowia Matki Polki w Łodzi
  9. Klinika Transplantacji Szpiku i Onkohematologii, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie — Państwowy Instytut Badawczy, Oddział w Gliwicach
  10. Klinika Onkologii Klinicznej, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie — Państwowy Instytut Badawczy, Oddział w Krakowie
  11. Zakład Patologii i Diagnostyki Laboratoryjnej, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie — Państwowy Instytut Badawczy w Warszawie
  12. Zakład Diagnostyki Hematologicznej, Instytut Hematologii i Transfuzjologii w Warszawie
  13. Zakład Radioterapii, Uniwersytet Medyczny w Łodzi
  14. Klinika Nowotworów Głowy i Szyi, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie — Państwowy Instytut Badawczy w Warszawie
  15. Uniwersytet Jagielloński Collegium Medicum, Wydział Lekarski, Klinika Okulistyki i Onkologii Okulistycznej w Krakowie
  16. Klinika Endokrynologii Onkologicznej i Medycyny Nuklearnej, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie — Państwowy Instytut Badawczy w Warszawie
  17. SP ZOZ Ministerstwa Spraw Wewnętrznych z Warmińsko-Mazurskim Centrum Onkologii, Klinika Onkologii i Immunohematologii z Oddziałem Dziennym Terapii Onkologicznej w Olsztynie
  18. Stowarzyszenie Pomocy Chorym na Mięsaki i Czerniaki "Sarcoma"
  19. Zakład Rehabilitacji, Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie — Państwowy Instytut Badawczy w Warszawie
  20. Warszawski Uniwersytet Medyczny, Szpital Kliniczny im. Dzieciątka Jezus
  21. Wojskowy Instytut Medyczny, Centralny Szpital Kliniczny MON w Warszawie
  22. Klinika Nowotworów Płuca i Klatki Piersiowej, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie — Państwowy Instytut Badawczy w Warszawie

dostęp otwarty

Tom 8, Nr 6 (2022)
WYTYCZNE POSTĘPOWANIA DIAGNOSTYCZNO-TERAPEUTYCZNEGO
Opublikowany online: 2021-12-30

Streszczenie

Brak

Streszczenie

Brak

Pełny tekst:

Pokaż PDF Pokaż HTML
Pobierz cytowanie

Słowa kluczowe

czerniak; diagnostyka; terapia; immunoterapia; anty-PD-1; anti-CTLA-4; BRAF; MEK; biopsja węzła wartowniczego

Informacje o artykule
Tytuł

Postępowanie diagnostyczno-terapeutyczne u chorych na czerniaki — zalecenia ekspertów

Czasopismo

Onkologia w Praktyce Klinicznej - Edukacja

Numer

Tom 8, Nr 6 (2022)

Typ artykułu

Wytyczne / stanowisko ekspertów

Strony

387-423

Opublikowany online

2021-12-30

Wyświetlenia strony

1486

Wyświetlenia/pobrania artykułu

843

Rekord bibliograficzny

Onkol Prakt Klin Edu 2022;8(6):387-423.

Słowa kluczowe

czerniak
diagnostyka
terapia
immunoterapia
anty-PD-1
anti-CTLA-4
BRAF
MEK
biopsja węzła wartowniczego

Autorzy

Piotr Rutkowski
Piotr J. Wysocki
Katarzyna Kozak
Anna Nasierowska-Guttmejer
Arkadiusz Jeziorski
Wojciech M. Wysocki
Ewa Kalinka
Tomasz Świtaj
Grażyna Kamińska-Winciorek
Anna M. Czarnecka
Hanna Koseła-Paterczyk
Bożena Cybulska-Stopa
Piotr Wiśniewski
Anna Szumera-Ciećkiewicz
Marcin Zdzienicki
Marek Ziobro
Jacek Fijuth
Andrzej Kawecki
Andrzej Tysarowski
Bożena Romanowska-Dixon
Anna Markiewicz
Marek Dedecjus
Tomasz Kubiatowski
Kamil Dolecki
Hanna Tchórzewska-Korba
Lidia Rudnicka
Witold Owczarek
Maciej Krzakowski

Referencje (177)
  1. Rutkowski P. Złośliwe nowotwory skóry. Via Medica, Gdańsk 2014.
  2. Didkowska J, Wojciechowska U, Olasek P. Nowotwory złośliwe w Polsce w 2017 roku. Cancer in Poland in 2017. Krajowy Rejestr Nowotworów, Warszawa 2019.
  3. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy. http://onkologia.org.pl/raporty/ (05.04.2020).
  4. Yde SS, Sjoegren P, Heje M, et al. Mucosal Melanoma: a Literature Review. Curr Oncol Rep. 2018; 20(3): 28.
    CrossRefPubMed
  5. Meleti M, Leemans CR, de Bree R, et al. Head and neck mucosal melanoma: experience with 42 patients, with emphasis on the role of postoperative radiotherapy. Head Neck. 2008; 30(12): 1543–1551.
    CrossRefPubMed
  6. Rapini R, Golitz L, Greer R, et al. Primary malignant melanoma of the oral cavity. A review of 177 cases. Cancer. 1985; 55(7): 1543–1551, doi: 10.1002/1097-0142(19850401)55:7<1543::aid-cncr2820550722>3.0.co;2-f.
  7. Lotem M, Anteby S, Peretz T, et al. Mucosal melanoma of the female genital tract is a multifocal disorder. Gynecol Oncol. 2003; 88(1): 45–50.
    CrossRefPubMed
  8. Carvajal RD, Spencer SA, Lydiatt W. Mucosal melanoma: a clinically and biologically unique disease entity. J Natl Compr Canc Netw. 2012; 10(3): 345–356.
    CrossRefPubMed
  9. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998; 83(8): 1664–1678, doi: 10.1002/(sici)1097-0142(19981015)83:8<1664::aid-cncr23>3.0.co;2-g.
    PubMed
  10. Michielin O, van Akkooi ACJ, Ascierto PA, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019; 30(12): 1884–1901.
    CrossRefPubMed
  11. Wouters MW, Michielin O, Bastiaannet E, et al. ECCO essential requirements for quality cancer care: Melanoma. Crit Rev Oncol Hematol. 2018; 122: 164–178.
    CrossRefPubMed
  12. Michielin O, van Akkooi ACJ, Ascierto PA, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019; 30(12): 1884–1901.
    CrossRefPubMed
  13. Gajda M, Kaminska-Winciorek G. Do not let to be late: overview of reasons for melanoma delayed diagnosis. Asian Pac J Cancer Prev. 2014; 15(9): 3873–3877.
    CrossRefPubMed
  14. Kamińska-Winciorek G, Placek W. The most common mistakes on dermatoscopy of melanocytic lesions. Postepy Dermatol Alergol. 2015; 32(1): 33–39.
    CrossRefPubMed
  15. NCCN Guidelines. Cutaneous melanoma version 1.2021.
  16. Gershenwald JE, Scolyer RA, Hess KR. Melanoma of the skin. AJCC Cancer Staging Manual. Eight Edition. Springer 2017.
  17. Elder E, Massi D, Scolyer RA. Classification of Skin Tumours 4th Edition. International Agency for Research on Cancer 2018.
  18. Cheng L, Lopez-Beltran A, Massari F, et al. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol. 2018; 31(1): 24–38.
    CrossRefPubMed
  19. Vanni I, Tanda ET, Spagnolo F, et al. The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape. Front Mol Biosci. 2020; 7: 113.
    CrossRefPubMed
  20. Raghavan SS, Peternel S, Mully TW, et al. Spitz melanoma is a distinct subset of spitzoid melanoma. Mod Pathol. 2020; 33(6): 1122–1134.
    CrossRefPubMed
  21. Giubellino A, Zhou Y. Molecular Characterization of Spitz Tumors: An Approach to Improve Disease Diagnosis and Classification. J Mol Genet Med. 2019; 13: 417.
  22. Hayward NK, Wilmott JS, Waddell N, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017; 545(7653): 175–180.
    CrossRefPubMed
  23. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27(36): 6199–6206.
    CrossRefPubMed
  24. Morton DL, Thompson JF, Cochran AJ, et al. MSLT Group. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014; 370(7): 599–609.
    CrossRefPubMed
  25. Wong SL, Balch CM, Hurley P, et al. American Society of Clinical Oncology, Society of Surgical Oncology. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol. 2012; 30(23): 2912–2918.
    CrossRefPubMed
  26. Michielin O, van Akkooi A, Lorigan P, et al. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020; 31(11): 1449–1461.
    CrossRefPubMed
  27. Nowecki ZI, Rutkowski P, Michej W. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3). Ann Surg Oncol. 2008; 15(8): 2223–2234.
    CrossRefPubMed
  28. Uppal A, Stern S, Thompson JF, et al. MSLT Group, MSLT Cooperative Group. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol. 2010; 17(12): 3324–3329.
    CrossRefPubMed
  29. Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016; 17(6): 757–767.
    CrossRefPubMed
  30. van Akkooi ACJ, Nowecki ZI, Voit C, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg. 2008; 248(6): 949–955.
    CrossRefPubMed
  31. Testori A, Rutkowski P, Marsden J, et al. Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol. 2009; 20 Suppl 6: vi22–vi29.
    CrossRefPubMed
  32. Kamposioras K, Pentheroudakis G, Pectasides D, et al. Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol. 2011; 78(2): 112–126.
    CrossRefPubMed
  33. Mali B, Jarm T, Snoj M, et al. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol. 2013; 39(1): 4–16.
    CrossRefPubMed
  34. Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33(25): 2780–2788.
    CrossRefPubMed
  35. Ballantyne AJ. Malignant melanoma of the skin of the head and neck. An analysis of 405 cases. Am J Surg. 1970; 120(4): 425–431.
    CrossRefPubMed
  36. Smith HG, Bagwan I, Board RE, et al. Ano-uro-genital mucosal melanoma UK national guidelines. Eur J Cancer. 2020; 135: 22–30.
    CrossRefPubMed
  37. McLean N, Tighiouart M, Muller S. Primary mucosal melanoma of the head and neck. Comparison of clinical presentation and histopathologic features of oral and sinonasal melanoma. Oral Oncol. 2008; 44(11): 1039–1046.
    CrossRefPubMed
  38. Agrawal S, Kane JM, Guadagnolo BA, et al. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer. 2009; 115(24): 5836–5844.
    CrossRefPubMed
  39. Bullard KM, Tuttle TM, Rothenberger DA, et al. Surgical therapy for anorectal melanoma. J Am Coll Surg. 2003; 196(2): 206–211.
    CrossRefPubMed
  40. Kiran RP, Rottoli M, Pokala N, et al. Long-term outcomes after local excision and radical surgery for anal melanoma: data from a population database. Dis Colon Rectum. 2010; 53(4): 402–408.
    CrossRefPubMed
  41. Malaguarnera G, Madeddu R, Catania VE, et al. Anorectal mucosal melanoma. Oncotarget. 2018; 9(9): 8785–8800.
    CrossRefPubMed
  42. Lee AY, Berman RS. Management of Noncutaneous Melanomas. Surg Oncol Clin N Am. 2020; 29(3): 387–400.
    CrossRefPubMed
  43. Pittaka M, Kardamakis D, Spyropoulou D. Comparison of International Guidelines on Mucosal Melanoma of the Head and Neck: A Comprehensive Review of the Role of Radiation Therapy. In Vivo. 2016; 30: 165–170.
  44. Eggermont AMM, Gore M. Randomized adjuvant therapy trials in melanoma: surgical and systemic. Semin Oncol. 2007; 34(6): 509–515.
    CrossRefPubMed
  45. Sondak VK, Gonzalez RJ, Kudchadkar R. Adjuvant therapy for melanoma: a surgical perspective. Surg Oncol Clin N Am. 2011; 20(1): 105–114.
    CrossRefPubMed
  46. Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. 2016; 375(19): 1845–1855.
    CrossRefPubMed
  47. Eggermont AMM, Suciu S, Testori A, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer. 2012; 48(2): 218–225.
    CrossRefPubMed
  48. Weber J, Mandala M, Del Vecchio M, et al. CheckMate 238 Collaborators. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017; 377(19): 1824–1835.
    CrossRefPubMed
  49. Eggermont A, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015; 16(5): 522–530.
    CrossRefPubMed
  50. Weber J, Mandalà M, Vecchio MD, et al. Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238). J Clin Oncol. 2018; 36(15_suppl): 9502–9502.
    CrossRef
  51. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018; 378(19): 1789–1801.
    CrossRefPubMed
  52. Eggermont AMM, Blank CU, Mandala M, et al. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. J Clin Oncol. 2020; 38(33): 3925–3936.
    CrossRefPubMed
  53. Eggermont A, Blank C, Mandalà M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. The Lancet Oncology. 2021; 22(5): 643–654.
    CrossRef
  54. Eggermont A, Kicinski M, Blank C, et al. Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma. NEJM Evidence. 2022; 1(11).
    CrossRef
  55. Luke J, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022; 399(10336): 1718–1729.
    CrossRefPubMed
  56. Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017; 377(19): 1813–1823.
    CrossRefPubMed
  57. Hauschild A, Dummer R, Schadendorf D, et al. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected V600-Mutant Stage III Melanoma. J Clin Oncol. 2018; 36(35): 3441–3449.
    CrossRefPubMed
  58. Dummer R, Hauschild A, Santinami M, et al. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2020; 383(12): 1139–1148.
    CrossRefPubMed
  59. Burmeister B, Henderson M, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol. 2012; 13(6): 589–597.
    CrossRefPubMed
  60. Ballo MT, Ang KK. Radiotherapy for cutaneous malignant melanoma: rationale and indications. Oncology (Williston Park). 2004; 18(1): 99–107; discussion 107.
    PubMed
  61. Henderson M, Burmeister B, Ainslie J, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol. 2015; 16(9): 1049–1060.
    CrossRefPubMed
  62. Rutkowski P, Kiprian D, Dudzisz-Śledź M, et al. Management of brain metastases in melanoma. Oncol Clin Pract. 2019; 15(1): 51–61.
    CrossRef
  63. Rutkowski P, Kiprian D, Dudzisz-Śledź M, et al. Management of melanoma metastases in the brain. Nowotwory. Journal of Oncology. 2019; 69(3-4): 86–96.
    CrossRef
  64. Fogarty G, Dolven-Jacobsen K, Morton R, et al. Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs). Journal of Clinical Oncology. 2019; 37(15_suppl): 9500–9500.
    CrossRef
  65. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8): 711–723.
    CrossRefPubMed
  66. Świtaj T, Wysocki P, Wojtukiewicz M, et al. Ipilimumab — postępy w terapii chorych na zaawansowanego czerniaka. Onkol Prakt Klin. 2011; 7: 231–245.
  67. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15(23): 7412–7420.
    CrossRefPubMed
  68. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372(4): 320–330.
    CrossRefPubMed
  69. Weber J, D'Angelo S, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16(4): 375–384.
    CrossRefPubMed
  70. Robert C, Schachter J, Long GV, et al. KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015; 372(26): 2521–2532.
    CrossRefPubMed
  71. Robert C, Long GV, Brady B, et al. Five-Year Outcomes With Nivolumab in Patients With Wild-Type Advanced Melanoma. J Clin Oncol. 2020; 38(33): 3937–3946.
    CrossRefPubMed
  72. Valsecchi ME, Larkin J, Hodi FS, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(13): 1270–1271.
    CrossRefPubMed
  73. Robert C, Ribas A, Hamid O, et al. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J Clin Oncol. 2018; 36(17): 1668–1674.
    CrossRefPubMed
  74. Wolchok J, Chiarion-Sileni V, Gonzalez R, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017; 377(14): 1345–1356.
    CrossRef
  75. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019; 381(16): 1535–1546.
    CrossRefPubMed
  76. Shoushtari A, Wagstaff J, Ascierto P, et al. CheckMate 067: Long-term outcomes in patients with mucosal melanoma. J Clin Oncol. 2020; 38(15_suppl): 10019–10019.
    CrossRef
  77. D'Angelo SP, Larkin J, Sosman JA, et al. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. J Clin Oncol. 2017; 35(2): 226–235.
    CrossRefPubMed
  78. Li J, Kan H, Zhao L, et al. Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review. Ther Adv Med Oncol. 2020; 12: 1758835920922028.
    CrossRefPubMed
  79. Long G, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018; 19(5): 672–681.
    CrossRef
  80. Tawbi HA, Forsyth PA, Algazi A, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018; 379(8): 722–730.
    CrossRefPubMed
  81. Chapman PB, Hauschild A, Robert C, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26): 2507–2516.
    CrossRefPubMed
  82. Hauschild A, Grob JJ, Demidov L, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. The Lancet. 2012; 380(9839): 358–365.
    CrossRefPubMed
  83. Flaherty KT, Robert C, Hersey P, et al. METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012; 367(2): 107–114.
    CrossRefPubMed
  84. Ascierto P, Berking C, Agarwala S, et al. Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J Clin Oncol. 2012; 30(15_suppl): 8511–8511.
    CrossRef
  85. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015; 372(1): 30–39.
    CrossRefPubMed
  86. Long G, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. The Lancet. 2015; 386(9992): 444–451.
    CrossRefPubMed
  87. Ascierto P, McArthur G, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016; 17(9): 1248–1260.
    CrossRefPubMed
  88. Robert C, Karaszewska B, Schachter J, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma. Annals of Oncology. 2016; 27: vi575.
    CrossRef
  89. Dummer R, Ascierto P, Gogas H, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018; 19(5): 603–615.
    CrossRefPubMed
  90. Dummer R, Ascierto P, Gogas H, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018; 19(10): 1315–1327.
    CrossRefPubMed
  91. Robert C, Grob JJ, Stroyakovskiy D, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019; 381(7): 626–636.
    CrossRefPubMed
  92. Ascierto P, Dréno B, Larkin J, et al. 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. Clinical Cancer Research. 2021; 27(19): 5225–5235.
    CrossRef
  93. Ascierto PA, Dummer R, Gogas HJ, et al. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur J Cancer. 2020; 126: 33–44.
    CrossRefPubMed
  94. Schreuer M, Jansen Y, Planken S, et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncol. 2017; 18(4): 464–472.
    CrossRefPubMed
  95. Valpione S, Carlino M, Mangana J, et al. Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study. J Clin Oncol. 2017; 35(15_suppl): 9512–9512.
    CrossRef
  96. Cybulska-Stopa B, Rogala P, Czarnecka AM, et al. BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. Melanoma Res. 2020; 30(5): 465–471.
    CrossRefPubMed
  97. Guo J, Si Lu, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011; 29(21): 2904–2909.
    CrossRefPubMed
  98. Czarnecka AM, Teterycz P, Mariuk-Jarema A, et al. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice. Target Oncol. 2019; 14(6): 729–742.
    CrossRefPubMed
  99. Keilholz U, Ascierto PA, Dummer R, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020; 31(11): 1435–1448.
    CrossRefPubMed
  100. Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020; 395(10240): 1835–1844.
    CrossRefPubMed
  101. Tawbi HA, Schadendorf D, Lipson EJ, et al. RELATIVITY-047 Investigators. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022; 386(1): 24–34.
    CrossRefPubMed
  102. Arié A, Yamamoto T. Lymphedema secondary to melanoma treatments: diagnosis, evaluation, and treatments. Glob Health Med. 2020; 2(4): 227–234.
    CrossRefPubMed
  103. Malicka I, Siewierska K. In: Woźniewski M. ed. Fizjoterapia w onkologii. PZWL 2020.
  104. Campanholi L, Duprat J, Fregnani J. Analysis of physical therapy in patients who had radical lymphadenectomy for cutaneous melanoma. Applied Cancer Research. 2012; 32(1): 12–15.
  105. Gjorup CA, Groenvold M, Hendel HW, et al. Health-related quality of life in melanoma patients: Impact of melanoma-related limb lymphoedema. Eur J Cancer. 2017; 85: 122–132.
    CrossRefPubMed
  106. Gjorup CA, Hendel HW, Zerahn Bo, et al. Volume and Tissue Composition Changes Measured with Dual-Energy X-Ray Absorptiometry in Melanoma-Related Limb Lymphedema. Lymphat Res Biol. 2017; 15(3): 274–283.
    CrossRefPubMed
  107. Jassem J, Duchnowska R, Kawecki A, et al. Badania kontrolne po leczeniu w najczęstszych nowotworach litych u dorosłych. Nowotwory. Journal of Oncology. 2014; 64(5): 415–435.
    CrossRef
  108. Rutkowski P, Lugowska I. Follow-up in melanoma patients. Memo. 2014; 7(2): 83–86.
    CrossRefPubMed
  109. Rodrigues M, Koning Lde, Coupland SE, et al. UM Cure 2020 Consortium. So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020. Cancers (Basel). 2019; 11(7).
    CrossRefPubMed
  110. Wojciechowska Urszula, Didkowska Joanna, Irmina Michałek, Paweł Olasek, Agata Ciuba. Nowotwory złośliwe w Polsce w 2018 roku. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy. http://onkologia.org.pl/publikacje/.
  111. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011; 118(9): 1881–1885.
    CrossRefPubMed
  112. Virgili G, Gatta G, Ciccolallo L, et al. EUROCARE Working Group. Incidence of uveal melanoma in Europe. Ophthalmology. 2007; 114(12): 2309–2315.
    CrossRefPubMed
  113. Kivelä T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol. 2009; 93(9): 1129–1131.
    CrossRefPubMed
  114. Shields CL, Kaliki S, Cohen MN, et al. Prognosis of uveal melanoma based on race in 8100 patients: The 2015 Doyne Lecture. Eye (Lond). 2015; 29(8): 1027–1035.
    CrossRefPubMed
  115. Al-Jamal RT, Cassoux N, Desjardins L, et al. The Pediatric Choroidal and Ciliary Body Melanoma Study: A Survey by the European Ophthalmic Oncology Group. Ophthalmology. 2016; 123(4): 898–907.
    CrossRefPubMed
  116. Kivelä T. Prevalence and epidemiology of ocular melanoma. In: Murray T, Boldt HC. ed. Ocular Melanoma: Advances in Diagnostic and Therapeutic Strategies. Future Science, London 2014: 21–38.
  117. Żygulska-Mach H. Epidemiologia czerniaka oka. Współczesna Onkologia. 1998; 8: 226–227.
  118. Cabanis EEA, Bourgeois H, Iba-Zizen MT. Imagerie en ophtalmologie. Masson, Paris 1996: 486–502.
  119. Jager MJ, Shields CL, Cebulla CM, et al. Uveal melanoma. Nat Rev Dis Primers. 2020; 6(1): 24.
    CrossRefPubMed
  120. Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009; 127(8): 989–998.
    CrossRefPubMed
  121. Berus T, Halon A, Markiewicz A, et al. Clinical, Histopathological and Cytogenetic Prognosticators in Uveal Melanoma - A Comprehensive Review. Anticancer Res. 2017; 37(12): 6541–6549.
    CrossRefPubMed
  122. McLean I, Foster W, Zimmerman L, et al. Modifications of Callender's Classification of Uveal Melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol. 1983; 96(4): 502–509.
    CrossRef
  123. Folberg R, Rummelt V, Ginderdeuren RPV, et al. The Prognostic Value of Tumor Blood Vessel Morphology in Primary Uveal Melanoma. Ophthalmology. 1993; 100(9): 1389–1398.
    CrossRef
  124. Bronkhorst IHG, Jager MJ. Inflammation in uveal melanoma. Eye (Lond). 2013; 27(2): 217–223.
    CrossRefPubMed
  125. Harbour JW. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010; 330: 1410–1413.
  126. Shields JA, Shields CL. Management of posterior uveal melanoma: past, present, and future: the 2014 Charles L. Schepens lecture. Ophthalmology. 2015; 122(2): 414–428.
    CrossRefPubMed
  127. Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019; 29(6): 561–568.
    CrossRefPubMed
  128. AJCC Ophthalmic Oncology Task Force. International Validation of the American Joint Committee on Cancer's 7th Edition Classification of Uveal Melanoma. JAMA Ophthalmol. 2015; 133(4): 376–383.
    CrossRefPubMed
  129. Damato EM, Damato BE. Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients. Ophthalmology. 2012; 119(8): 1582–1589.
    CrossRefPubMed
  130. Romanowska-Dixon B, Jakubowska B, Karska-Basta I. et al. Uveal Tumors. Differential diagnosis of intraocular tumors. In: Romanowska-Dixon B, Jager MJ, Coupland S. ed. Ocular Oncology. PZWL Wydawnictwo Lekarskie, Warszawa 2020: 105–369.
  131. Shields J, Shields C, Ehya H, et al. Fine-needle Aspiration Biopsy of Suspected Intraocular Tumors. Ophthalmology. 1993; 100(11): 1677–1684.
    CrossRef
  132. NCCN Guidelines. Uveal Melanoma. Version 3.2020.
  133. Shields CL, Dalvin LA, Ancona-Lezama D, et al. CHOROIDAL NEVUS IMAGING FEATURES IN 3,806 CASES AND RISK FACTORS FOR TRANSFORMATION INTO MELANOMA IN 2,355 CASES: The 2020 Taylor R. Smith and Victor T. Curtin Lecture. Retina. 2019; 39(10): 1840–1851.
    CrossRefPubMed
  134. Shields JA, Mashayekhi A, Ra S, et al. Pseudomelanomas of the posterior uveal tract: the 2006 Taylor R. Smith Lecture. Retina. 2005; 25(6): 767–771.
    CrossRefPubMed
  135. Shields CL. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106consecutive patients. Arch Ophthalmol. 2000; 118: 1219–1228.
  136. Melia BM, Abramson DH, Albert DM, et al. Collaborative Ocular Melanoma Study Group. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology. 2001; 108(2): 348–366.
    CrossRefPubMed
  137. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol. 2006; 124(12): 1684–1693.
    CrossRefPubMed
  138. American Brachytherapy Society - Ophthalmic Oncology Task Force. Electronic address: paulfinger@eyecancer.com, ABS – OOTF Committee. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014; 13(1): 1–14.
    CrossRefPubMed
  139. Straatsma BR. Golden Jubilee Lecture. Randomised clinical trials of choroidal melanoma treatment. Indian J Ophthalmol. 2003; 51(1): 17–23.
    PubMed
  140. Diener-West M, Earle JD, Fine SL, et al. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol. 2001; 119(7): 969–982.
    CrossRefPubMed
  141. Mortality in Patients With Small Choroidal Melanoma. Archives of Ophthalmology. 1997; 115(7): 886.
    CrossRef
  142. Gragoudas ES, Lane AM, Munzenrider J, et al. Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. Trans Am Ophthalmol Soc. 2002; 100: 43–48.
    PubMed
  143. Damato B. The role of eyewall resection in uveal melanoma management. Int Ophthalmol Clin. 2006; 46(1): 81–93.
    CrossRefPubMed
  144. Konstantinidis L, Groenewald C, Coupland SE, et al. Long-term outcome of primary endoresection of choroidal melanoma. Br J Ophthalmol. 2014; 98(1): 82–85.
    CrossRefPubMed
  145. Kubicka-Trząska A, Morawski K, Markiewicz A, et al. Prevention and treatment of the toxic tumour syndrome following primary proton beam therapy of choroidal melanomas. Arch Med Sci Civil Dis. 2020; 5(1): 22–28.
    CrossRef
  146. Turkoglu E, Pointdujour-Lim R, Mashayekhi A, et al. PHOTODYNAMIC THERAPY AS PRIMARY TREATMENT FOR SMALL CHOROIDAL MELANOMA. Retina. 2019; 39(7): 1319–1325.
    CrossRef
  147. Rundle P. Treatment of posterior uveal melanoma with multi-dose photodynamic therapy. Br J Ophthalmol. 2014; 98(4): 494–497.
    CrossRefPubMed
  148. Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019; 29(6): 561–568.
    CrossRefPubMed
  149. Fiorentini G, Aliberti C, Del Conte A, et al. Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. 2009; 23(1): 131–137.
  150. Pelster MS, Gruschkus SK, Bassett R, et al. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. J Clin Oncol. 2021; 39(6): 599–607.
    CrossRefPubMed
  151. Piulats J, Espinosa E, Merino Ld, et al. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J Clin Oncol. 2021; 39(6): 586–598.
    CrossRef
  152. Rodriguez-Vidal C, Fernandez-Diaz D, Fernandez-Marta B, et al. Treatment of Metastatic Uveal Melanoma: Systematic Review. Cancers (Basel). 2020; 12(9).
    CrossRefPubMed
  153. Sacco JJ, Carvajal R, Butler MO, et al. 64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM). Annals of Oncology. 2020; 31: S1442–S1443.
    CrossRef
  154. Nathan P, Hassel JC, Rutkowski P, et al. IMCgp100-202 Investigators. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021; 385(13): 1196–1206.
    CrossRefPubMed
  155. Shields JA, Shields CL. Intraocular Tumors: An Atlas and Textbook 3rd ed. Wolters Kluwer 2015.
  156. Barker CA, Salama AK. New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma. J Natl Compr Canc Netw. 2018; 16(5S): 646–650.
    CrossRefPubMed
  157. Damato B. In: Joussen AM, Gardner TW, Kirchhof B, Ryan SJ. ed. Retinal Vascular Disease. Springer 2007: 582–591.
  158. Finger P. Anti–Vascular Endothelial Growth Factor Bevacizumab (Avastin) for Radiation Retinopathy. Archives of Ophthalmology. 2007; 125(6): 751.
    CrossRef
  159. Nathan P, et al. Uveal melanoma UK national guidelines. Eur J Cancer. 2015; 51: 2404–2412.
  160. Blum ES, Yang J, Komatsubara KM, et al. Clinical Management of Uveal and Conjunctival Melanoma. Oncology (Williston Park). 2016; 30(1): 34–43.
  161. McLaughlin C, Wu XC, Jemal A, et al. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005; 103(5): 1000–1007.
    CrossRef
  162. Shields CL, Markowitz JS, Belinsky I, et al. Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases. Ophthalmology. 2011; 118(2): 389–95.e1.
    CrossRefPubMed
  163. Missotten GS, Keijser S, De Keizer RJW, et al. Conjunctival melanoma in the Netherlands: a nationwide study. Invest Ophthalmol Vis Sci. 2005; 46(1): 75–82.
    CrossRefPubMed
  164. Shields CL, Shields CL, Shields JA, et al. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol. 2000; 118(11): 1497–1507.
    CrossRefPubMed
  165. Wong JR, Nanji AA, Galor A, et al. Management of conjunctival malignant melanoma: a review and update. Expert Rev Ophthalmol. 2014; 9(3): 185–204.
    CrossRefPubMed
  166. Paridaens AD, McCartney AC, Minassian DC, et al. Orbital exenteration in 95 cases of primary conjunctival malignant melanoma. Br J Ophthalmol. 1994; 78(7): 520–528.
    CrossRefPubMed
  167. Norregaard JC, Gerner N, Jensen OA, et al. Malignant melanoma of the conjunctiva: occurrence and survival following surgery and radiotherapy in a Danish population. Graefes Arch Clin Exp Ophthalmol. 1996; 234(9): 569–572.
    CrossRefPubMed
  168. Finger PT, Czechonska G, Liarikos S. Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia. Br J Ophthalmol. 1998; 82(5): 476–479.
    CrossRef
  169. Kurli M, Finger PT. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience. Graefes Arch Clin Exp Ophthalmol. 2005; 243(11): 1108–1114.
    CrossRefPubMed
  170. Demirci H, McCormick SA, Finger PT. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations. Arch Ophthalmol. 2000; 118(7): 885–891.
    PubMed
  171. Ditta LC, Shildkrot Y, Wilson MW. Outcomes in 15 patients with conjunctival melanoma treated with adjuvant topical mitomycin C: complications and recurrences. Ophthalmology. 2011; 118(9): 1754–1759.
    CrossRefPubMed
  172. Russell HC, Chadha V, Lockington D, et al. Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications. Br J Ophthalmol. 2010; 94(10): 1316–1321.
    CrossRefPubMed
  173. Khong JJ, Muecke J. Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol. 2006; 90(7): 819–822.
    CrossRefPubMed
  174. Finger PT, Sedeek RW, Chin KJ. Topical interferon alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex. Am J Ophthalmol. 2008; 145(1): 124–129.
    CrossRefPubMed
  175. Herold TR, Hintschich C. Interferon alpha for the treatment of melanocytic conjunctival lesions. Graefes Arch Clin Exp Ophthalmol. 2010; 248(1): 111–115.
    CrossRefPubMed
  176. Esmaeli B. Patterns of regional and distant metastasis in patients with conjunctival melanoma Experience at a cancer center over four decades. Ophthalmology. 2001; 108(11): 2101–2105.
    CrossRef
  177. Tuomaala S, Kivelä T. Metastatic pattern and survival in disseminated conjunctival melanoma: implications for sentinel lymph node biopsy. Ophthalmology. 2004; 111(4): 816–821.
    CrossRefPubMed

Regulamin

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

 

Wydawcą serwisu jest  VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl